Case Reports in Infectious Diseases / 2018 / Article / Tab 1

Case Report

In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways

Table 1

Antimicrobial susceptibility, β-lactamase overproduction assay, and carbapenemase production assay of P. aeruginosa strains.

IsolateMIC (µg/ml)aCarbaNP
FEPbPTZbCZAcC/TcIMIbMERbDORbCAZc
MHd+ CLOXd

PA231216>128/44/42/432326411NEG
PA2428>32>128/4>64/464/4323216≥25624NEG

HOU236532>128/44/42/4168482NEG
HOU23666464/4>64/4>128/443216≥256≥256NEG

aCAZ: ceftazidime; C/T: ceftolozane/tazobactam; CZA: ceftazidime/avibactam; DOR: doripenem; FEP: cefepime; IMI: imipenem; MER: meropenem; PTZ: piperacillin/tazobactam. bMIC determined by broth microdilution; cMIC determined by Etest; dceftazidime (CAZ) MIC as determined by Etest in the presence/absence of cloxacillin (CLOX) 1000 µg/ml.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.